Global Rivaroxaban Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
Table of Contents
1 Market Overview
- 1.1 Rivaroxaban Introduction
- 1.2 Market Analysis by Type
- 1.2.1 2.5 mg
- 1.2.2 10 mg
- 1.2.3 15 mg
- 1.2.4 20 mg
- 1.3 Market Analysis by Applications
- 1.3.1 Acute Coronary Syndrome (ACS)
- 1.3.2 Venous Thromboembolism (VTE)
- 1.4 Market Analysis by Regions
- 1.4.1 North America (United States, Canada and Mexico)
- 1.4.1.1 United States Market States and Outlook (2014-2024)
- 1.4.1.2 Canada Market States and Outlook (2014-2024)
- 1.4.1.3 Mexico Market States and Outlook (2014-2024)
- 1.4.2 Europe (Germany, France, UK, Russia and Italy)
- 1.4.2.1 Germany Market States and Outlook (2014-2024)
- 1.4.2.2 France Market States and Outlook (2014-2024)
- 1.4.2.3 UK Market States and Outlook (2014-2024)
- 1.4.2.4 Russia Market States and Outlook (2014-2024)
- 1.4.2.5 Italy Market States and Outlook (2014-2024)
- 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- 1.4.3.1 China Market States and Outlook (2014-2024)
- 1.4.3.2 Japan Market States and Outlook (2014-2024)
- 1.4.3.3 Korea Market States and Outlook (2014-2024)
- 1.4.3.4 India Market States and Outlook (2014-2024)
- 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
- 1.4.4 South America, Middle East and Africa
- 1.4.4.1 Brazil Market States and Outlook (2014-2024)
- 1.4.4.2 Egypt Market States and Outlook (2014-2024)
- 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
- 1.4.4.4 South Africa Market States and Outlook (2014-2024)
- 1.4.4.5 Turkey Market States and Outlook (2014-2024)
- 1.4.1 North America (United States, Canada and Mexico)
- 1.5 Market Dynamics
- 1.5.1 Market Opportunities
- 1.5.2 Market Risk
- 1.5.3 Market Driving Force
2 Manufacturers Profiles
- 2.1 Bayer
- 2.1.1 Business Overview
- 2.1.2 Rivaroxaban Type and Applications
- 2.1.2.1 Product A
- 2.1.2.2 Product B
- 2.1.3 Bayer Rivaroxaban Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
- 2.2 J&J
- 2.2.1 Business Overview
- 2.2.2 Rivaroxaban Type and Applications
- 2.2.2.1 Product A
- 2.2.2.2 Product B
- 2.2.3 J&J Rivaroxaban Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global Rivaroxaban Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
- 3.1 Global Rivaroxaban Sales and Market Share by Manufacturer (2017-2018)
- 3.2 Global Rivaroxaban Revenue and Market Share by Manufacturer (2017-2018)
- 3.3 Market Concentration Rate
- 3.3.1 Top 3 Rivaroxaban Manufacturer Market Share in 2018
- 3.3.2 Top 6 Rivaroxaban Manufacturer Market Share in 2018
- 3.4 Market Competition Trend
4 Global Rivaroxaban Market Analysis by Regions
- 4.1 Global Rivaroxaban Sales, Revenue and Market Share by Regions
- 4.1.1 Global Rivaroxaban Sales and Market Share by Regions (2014-2019)
- 4.1.2 Global Rivaroxaban Revenue and Market Share by Regions (2014-2019)
- 4.2 North America Rivaroxaban Sales and Growth Rate (2014-2019)
- 4.3 Europe Rivaroxaban Sales and Growth Rate (2014-2019)
- 4.4 Asia-Pacific Rivaroxaban Sales and Growth Rate (2014-2019)
- 4.5 South America Rivaroxaban Sales and Growth Rate (2014-2019)
- 4.6 Middle East and Africa Rivaroxaban Sales and Growth Rate (2014-2019)
5 North America Rivaroxaban by Country
- 5.1 North America Rivaroxaban Sales, Revenue and Market Share by Country
- 5.1.1 North America Rivaroxaban Sales and Market Share by Country (2014-2019)
- 5.1.2 North America Rivaroxaban Revenue and Market Share by Country (2014-2019)
- 5.2 United States Rivaroxaban Sales and Growth Rate (2014-2019)
- 5.3 Canada Rivaroxaban Sales and Growth Rate (2014-2019)
- 5.4 Mexico Rivaroxaban Sales and Growth Rate (2014-2019)
6 Europe Rivaroxaban by Country
- 6.1 Europe Rivaroxaban Sales, Revenue and Market Share by Country
- 6.1.1 Europe Rivaroxaban Sales and Market Share by Country (2014-2019)
- 6.1.2 Europe Rivaroxaban Revenue and Market Share by Country (2014-2019)
- 6.2 Germany Rivaroxaban Sales and Growth Rate (2014-2019)
- 6.3 UK Rivaroxaban Sales and Growth Rate (2014-2019)
- 6.4 France Rivaroxaban Sales and Growth Rate (2014-2019)
- 6.5 Russia Rivaroxaban Sales and Growth Rate (2014-2019)
- 6.6 Italy Rivaroxaban Sales and Growth Rate (2014-2019)
7 Asia-Pacific Rivaroxaban by Country
- 7.1 Asia-Pacific Rivaroxaban Sales, Revenue and Market Share by Country
- 7.1.1 Asia-Pacific Rivaroxaban Sales and Market Share by Country (2014-2019)
- 7.1.2 Asia-Pacific Rivaroxaban Revenue and Market Share by Country (2014-2019)
- 7.2 China Rivaroxaban Sales and Growth Rate (2014-2019)
- 7.3 Japan Rivaroxaban Sales and Growth Rate (2014-2019)
- 7.4 Korea Rivaroxaban Sales and Growth Rate (2014-2019)
- 7.5 India Rivaroxaban Sales and Growth Rate (2014-2019)
- 7.6 Southeast Asia Rivaroxaban Sales and Growth Rate (2014-2019)
8 South America Rivaroxaban by Country
- 8.1 South America Rivaroxaban Sales, Revenue and Market Share by Country
- 8.1.1 South America Rivaroxaban Sales and Market Share by Country (2014-2019)
- 8.1.2 South America Rivaroxaban Revenue and Market Share by Country (2014-2019)
- 8.2 Brazil Rivaroxaban Sales and Growth Rate (2014-2019)
- 8.3 Argentina Rivaroxaban Sales and Growth Rate (2014-2019)
- 8.4 Colombia Rivaroxaban Sales and Growth Rate (2014-2019)
9 Middle East and Africa Rivaroxaban by Countries
- 9.1 Middle East and Africa Rivaroxaban Sales, Revenue and Market Share by Country
- 9.1.1 Middle East and Africa Rivaroxaban Sales and Market Share by Country (2014-2019)
- 9.1.2 Middle East and Africa Rivaroxaban Revenue and Market Share by Country (2014-2019)
- 9.2 Saudi Arabia Rivaroxaban Sales and Growth Rate (2014-2019)
- 9.3 Turkey Rivaroxaban Sales and Growth Rate (2014-2019)
- 9.4 Egypt Rivaroxaban Sales and Growth Rate (2014-2019)
- 9.5 Nigeria Rivaroxaban Sales and Growth Rate (2014-2019)
- 9.6 South Africa Rivaroxaban Sales and Growth Rate (2014-2019)
10 Global Rivaroxaban Market Segment by Type
- 10.1 Global Rivaroxaban Sales, Revenue and Market Share by Type (2014-2019)
- 10.1.1 Global Rivaroxaban Sales and Market Share by Type (2014-2019)
- 10.1.2 Global Rivaroxaban Revenue and Market Share by Type (2014-2019)
- 10.2 2.5 mg Sales Growth and Price
- 10.2.1 Global 2.5 mg Sales Growth (2014-2019)
- 10.2.2 Global 2.5 mg Price (2014-2019)
- 10.3 10 mg Sales Growth and Price
- 10.3.1 Global 10 mg Sales Growth (2014-2019)
- 10.3.2 Global 10 mg Price (2014-2019)
- 10.4 15 mg Sales Growth and Price
- 10.4.1 Global 15 mg Sales Growth (2014-2019)
- 10.4.2 Global 15 mg Price (2014-2019)
- 10.5 20 mg Sales Growth and Price
- 10.5.1 Global 20 mg Sales Growth (2014-2019)
- 10.5.2 Global 20 mg Price (2014-2019)
11 Global Rivaroxaban Market Segment by Application
- 11.1 Global Rivaroxaban Sales Market Share by Application (2014-2019)
- 11.2 Acute Coronary Syndrome (ACS) Sales Growth (2014-2019)
- 11.3 Venous Thromboembolism (VTE) Sales Growth (2014-2019)
12 Rivaroxaban Market Forecast (2019-2024)
- 12.1 Global Rivaroxaban Sales, Revenue and Growth Rate (2019-2024)
- 12.2 Rivaroxaban Market Forecast by Regions (2019-2024)
- 12.2.1 North America Rivaroxaban Market Forecast (2019-2024)
- 12.2.2 Europe Rivaroxaban Market Forecast (2019-2024)
- 12.2.3 Asia-Pacific Rivaroxaban Market Forecast (2019-2024)
- 12.2.4 South America Rivaroxaban Market Forecast (2019-2024)
- 12.2.5 Middle East and Africa Rivaroxaban Market Forecast (2019-2024)
- 12.3 Rivaroxaban Market Forecast by Type (2019-2024)
- 12.3.1 Global Rivaroxaban Sales Forecast by Type (2019-2024)
- 12.3.2 Global Rivaroxaban Market Share Forecast by Type (2019-2024)
- 12.4 Rivaroxaban Market Forecast by Application (2019-2024)
- 12.4.1 Global Rivaroxaban Sales Forecast by Application (2019-2024)
- 12.4.2 Global Rivaroxaban Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
- 13.1 Sales Channel
- 13.1.1 Direct Marketing
- 13.1.2 Indirect Marketing
- 13.1.3 Marketing Channel Future Trend
- 13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
- 15.1 Methodology
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Scope of the Report:
The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.
Bayer is the only supplier of Rivaroxaban enjoying production market share100% in 2015 and it will still in this situation until 2023.
The worldwide market for Rivaroxaban is expected to grow at a CAGR of roughly 9.4% over the next five years, will reach 10100 million US$ in 2024, from 5860 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Rivaroxaban in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Bayer
J&J
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
2.5 mg
10 mg
15 mg
20 mg
Market Segment by Applications, can be divided into
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Rivaroxaban product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Rivaroxaban, with price, sales, revenue and global market share of Rivaroxaban in 2017 and 2018.
Chapter 3, the Rivaroxaban competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rivaroxaban breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Rivaroxaban market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Rivaroxaban sales channel, distributors, customers, research findings and conclusion, appendix and data source.